Caris Life Sciences Inc(CAI) - 2025 Q3 - Earnings Call Presentation

Financial Performance - Total revenue increased to $216.8 million, a 113% year-over-year increase[10] - Molecular Profiling Services revenue increased to $207.6 million, a 121% year-over-year increase[10] - Pharma R&D Services revenue increased to $9.2 million, an 18% year-over-year increase[10] - Clinical ASP improved by 87%, from $2,184 to $4,089[13] - Achieved Positive Adjusted EBITDA of $51.2 million and GAAP Net Income of $24.3 million[13] - Achieved Positive Free Cash Flow of $55.3 million[13] - Q3 2025 gross margin was 68%, a ~2,432 bps improvement[13] Clinical Volume and Data - Clinical volume grew by 18%, completing 50,763 clinical cases[13] - The dataset surpassed 959,000+ genomic profiles and 660,000+ matched profiles including over 577,000 WES and 628,000 WTS[13] Guidance - Updated CY 2025 total revenue guidance to $720 - $730 million, representing 75-77% year-over-year growth[50] - Updated CY 2025 clinical therapy selection volume growth to 21-22% year-over-year[50] Partnership - 97 POA sites with now over 1,150 publications[13]